AbbVie signs to acquire Gilgamesh’s bretisilocin for $1.2bn

Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic

Discover AbbVie's substantial investment in psychedelic research through its acquisition of GM-2505 from Gilgamesh Pharmaceuticals.

AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space?

AbbVie (ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin (GM-2505), in a deal valued at up to $1.2 billion … AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space? Read More » The post AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psyched…

AbbVie signs to acquire Gilgamesh’s bretisilocin for $1.2bn

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for to $1.2bn.

Pharma Pulse: Novo Nordisk Plant Faces FDA Scrutiny, Off-Label GLP-1 Use Grows, and AbbVie Expands Psychiatry Pipeline

This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.